In patients who develop a VTE on palbociclib, do you discontinue therapy or continue as long as the patient is receiving adequate anticoagulation therapy?   

Thromboembolic events were seen in Paloma studies but the frequency was quite low and comparable with what would be expected to be associated with the presence of metastatic disease. Initially, there seemed to be a small increase in the patients taking palbociclib compared to the control arms. In ...